Ramin A Morshed1, Seunggu J Han2, Shawn L Hervey-Jumper1, Melike Pekmezci1, Irene Troncon1, Susan M Chang1, Nicholas A Butowski1, Mitchel S Berger3,4. 1. Department of Neurological Surgery, University of California, San Francisco, CA, USA. 2. Department of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA. 3. Department of Neurological Surgery, University of California, San Francisco, CA, USA. Mitchel.Berger@ucsf.edu. 4. Department of Neurological Surgery, University of California at San Francisco, 505 Parnassus Ave., Rm. M-779, San Francisco, CA, 94143-0112, USA. Mitchel.Berger@ucsf.edu.
Abstract
PURPOSE: WHO grade II gliomas are uncommon in patients over the age of 60, and there is a lack in consensus regarding their management. We present molecular tumor characteristics as well as clinical outcomes in patients over the age of 60 undergoing surgical resection of a WHO grade II glioma. METHODS: After receiving IRB approval, patients were identified through the UCSF Brain Tumor Center. Pathologic diagnosis was completed using WHO 2016 grading criteria. RESULTS: Twenty-six patients with a mean age of 66 years met inclusion criteria with a median follow-up of 5.2 years. Diagnoses included diffuse astrocytoma IDH-mutant (19.2%), diffuse astrocytoma IDH-wildtype (26.9%), Oligodendroglioma IDH-mutant and 1p/19q-codeleted (50%), and a rare case of mixed oligoastrocytoma (3.9%). 66% of astrocytoma IDH-wildtype tumors possessed TERT mutation. Median extent of resection was 75.4%. Progression-free (PFS) and overall survival (OS) were 23.5 and 62.6 months, respectively. Shorter PFS was associated with the astrocytoma IDH-wildtype subtype despite similar extent of resection and adjuvant treatment rates compared to the other subtypes. OS did not differ between subtypes. Malignant transformation and death were associated with larger preoperative and residual tumor volume. CONCLUSIONS: Older patients with diffuse gliomas may safely undergo aggressive treatment with surgical resection and adjuvant therapy. Elderly patients with low grade gliomas have worse clinical outcomes compared to their younger counterparts. This may be due to an increased frequency of diffuse astrocytoma IDH-wildtype tumors in this age group.
PURPOSE: WHO grade II gliomas are uncommon in patients over the age of 60, and there is a lack in consensus regarding their management. We present molecular tumor characteristics as well as clinical outcomes in patients over the age of 60 undergoing surgical resection of a WHO grade II glioma. METHODS: After receiving IRB approval, patients were identified through the UCSF Brain Tumor Center. Pathologic diagnosis was completed using WHO 2016 grading criteria. RESULTS: Twenty-six patients with a mean age of 66 years met inclusion criteria with a median follow-up of 5.2 years. Diagnoses included diffuse astrocytoma IDH-mutant (19.2%), diffuse astrocytoma IDH-wildtype (26.9%), Oligodendroglioma IDH-mutant and 1p/19q-codeleted (50%), and a rare case of mixed oligoastrocytoma (3.9%). 66% of astrocytoma IDH-wildtype tumors possessed TERT mutation. Median extent of resection was 75.4%. Progression-free (PFS) and overall survival (OS) were 23.5 and 62.6 months, respectively. Shorter PFS was associated with the astrocytoma IDH-wildtype subtype despite similar extent of resection and adjuvant treatment rates compared to the other subtypes. OS did not differ between subtypes. Malignant transformation and death were associated with larger preoperative and residual tumor volume. CONCLUSIONS: Older patients with diffuse gliomas may safely undergo aggressive treatment with surgical resection and adjuvant therapy. Elderly patients with low grade gliomas have worse clinical outcomes compared to their younger counterparts. This may be due to an increased frequency of diffuse astrocytoma IDH-wildtype tumors in this age group.
Entities:
Keywords:
Elderly; Low-grade glioma; Old age; Surgical resection
Authors: G Kaloshi; D Psimaras; K Mokhtari; C Dehais; C Houillier; Y Marie; F Laigle-Donadey; S Taillibert; R Guillevin; N Martin-Duverneuil; M Sanson; K Hoang-Xuan; J-Y Delattre Journal: Neurology Date: 2009-11-11 Impact factor: 9.910
Authors: Pooja Panwalkar; Jonathan Clark; Vijay Ramaswamy; Debra Hawes; Fusheng Yang; Christopher Dunham; Stephen Yip; Juliette Hukin; Yilun Sun; Matthew J Schipper; Lukas Chavez; Ashley Margol; Melike Pekmezci; Chan Chung; Adam Banda; Jill M Bayliss; Sarah J Curry; Mariarita Santi; Fausto J Rodriguez; Matija Snuderl; Matthias A Karajannis; Amanda M Saratsis; Craig M Horbinski; Anne-Sophie Carret; Beverly Wilson; Donna Johnston; Lucie Lafay-Cousin; Shayna Zelcer; David Eisenstat; Marianna Silva; Katrin Scheinemann; Nada Jabado; P Daniel McNeely; Marcel Kool; Stefan M Pfister; Michael D Taylor; Cynthia Hawkins; Andrey Korshunov; Alexander R Judkins; Sriram Venneti Journal: Acta Neuropathol Date: 2017-07-21 Impact factor: 17.088
Authors: K Lote; T Egeland; B Hager; B Stenwig; K Skullerud; J Berg-Johnsen; I Storm-Mathisen; H Hirschberg Journal: J Clin Oncol Date: 1997-09 Impact factor: 44.544
Authors: E Shaw; R Arusell; B Scheithauer; J O'Fallon; B O'Neill; R Dinapoli; D Nelson; J Earle; C Jones; T Cascino; D Nichols; R Ivnik; R Hellman; W Curran; R Abrams Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544
Authors: Francesco Pignatti; Martin van den Bent; Desmond Curran; Channa Debruyne; Richard Sylvester; Patrick Therasse; Denes Afra; Philippe Cornu; Michel Bolla; Charles Vecht; Abul B M F Karim Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Yoshikazu Okamoto; Pier-Luigi Di Patre; Christoph Burkhard; Sonja Horstmann; Benjamin Jourde; Michael Fahey; Danielle Schüler; Nicole M Probst-Hensch; M Gazi Yasargil; Yasuhiro Yonekawa; Urs M Lütolf; Paul Kleihues; Hiroko Ohgaki Journal: Acta Neuropathol Date: 2004-04-28 Impact factor: 17.088
Authors: Edward F Chang; Justin S Smith; Susan M Chang; Kathleen R Lamborn; Michael D Prados; Nicholas Butowski; Nicholas M Barbaro; Andrew T Parsa; Mitchel S Berger; Michael M McDermott Journal: J Neurosurg Date: 2008-11 Impact factor: 5.115
Authors: Jeanette E Eckel-Passow; Daniel H Lachance; Annette M Molinaro; Kyle M Walsh; Paul A Decker; Hugues Sicotte; Melike Pekmezci; Terri Rice; Matt L Kosel; Ivan V Smirnov; Gobinda Sarkar; Alissa A Caron; Thomas M Kollmeyer; Corinne E Praska; Anisha R Chada; Chandralekha Halder; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Roxanne Marshall; Shichun Zheng; Gerald F Reis; Alexander R Pico; Brian P O'Neill; Jan C Buckner; Caterina Giannini; Jason T Huse; Arie Perry; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Joseph Wiemels; John K Wiencke; Margaret R Wrensch; Robert B Jenkins Journal: N Engl J Med Date: 2015-06-10 Impact factor: 176.079
Authors: Andres Ramos-Fresnedo; Michael W Pullen; Carlos Perez-Vega; Ricardo A Domingo; Oluwaseun O Akinduro; Joao P Almeida; Paola Suarez-Meade; Lina Marenco-Hillembrand; Mark E Jentoft; Bernard R Bendok; Daniel M Trifiletti; Kaisorn L Chaichana; Alyx B Porter; Alfredo Quiñones-Hinojosa; Terence C Burns; Sani H Kizilbash; Erik H Middlebrooks; Wendy J Sherman Journal: J Neurooncol Date: 2022-02-17 Impact factor: 4.506
Authors: Tamara Ius; Edoardo Mazzucchi; Barbara Tomasino; Giada Pauletto; Giovanni Sabatino; Giuseppe Maria Della Pepa; Giuseppe La Rocca; Claudio Battistella; Alessandro Olivi; Miran Skrap Journal: Sci Rep Date: 2021-05-11 Impact factor: 4.379